Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Hill

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
BMJ (Clinical Research Ed.)|September 25, 2014
Centralising acute stroke services: study confounded by financial investmentAndrew M Hill
AIDS (London, England)|June 27, 2024
Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trialAndrew M Hill, Daniel Elbirt
HIV Clinical Trials|July 11, 2007
Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patientsAndrew M Hill, Colette Smith
Antiviral Therapy|October 1, 2004
HIV susceptibility testing--time for standardsAndrew M Hill, Amalio Telenti
The Lancet. Infectious Diseases|November 8, 2017
The unexpected success of NRTIs in second-line treatmentAndrew M Hill, Francois Venter
Journal of Virus Eradication|October 27, 2016
How can we achieve universal access to low-cost treatment for HIV?Andrew M Hill, Anton L Pozniak
Pharmacoeconomics|December 25, 2010
Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy eraMark A Boyd, Andrew M Hill
The Lancet. HIV|September 24, 2016
First-line integrase inhibitors for HIV-prices versus benefitsAnton L Pozniak, Andrew M Hill
Journal of Virus Eradication|August 1, 2017
The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countriesAndrew M Hill, Sanjay Nath, Bryony Simmons
International Journal of STD & AIDS|May 31, 2014
When can HIV clinical trials detect treatment effects on drug resistance?Andrew M Hill, Christiane Moecklinghoff, Ralph DeMasi
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
BMJ (Clinical Research Ed.)|September 25, 2014
Centralising acute stroke services: study confounded by financial investmentAndrew M Hill
AIDS (London, England)|June 27, 2024
Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trialAndrew M Hill, Daniel Elbirt
HIV Clinical Trials|July 11, 2007
Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patientsAndrew M Hill, Colette Smith
Antiviral Therapy|October 1, 2004
HIV susceptibility testing--time for standardsAndrew M Hill, Amalio Telenti
The Lancet. Infectious Diseases|November 8, 2017
The unexpected success of NRTIs in second-line treatmentAndrew M Hill, Francois Venter
Journal of Virus Eradication|October 27, 2016
How can we achieve universal access to low-cost treatment for HIV?Andrew M Hill, Anton L Pozniak
Pharmacoeconomics|December 25, 2010
Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy eraMark A Boyd, Andrew M Hill
The Lancet. HIV|September 24, 2016
First-line integrase inhibitors for HIV-prices versus benefitsAnton L Pozniak, Andrew M Hill
Journal of Virus Eradication|August 1, 2017
The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countriesAndrew M Hill, Sanjay Nath, Bryony Simmons
International Journal of STD & AIDS|May 31, 2014
When can HIV clinical trials detect treatment effects on drug resistance?Andrew M Hill, Christiane Moecklinghoff, Ralph DeMasi
Pageof 4